Your Health, We Care
Vibegron was approved for marketing by the PMDA of Japan on September 21, 2018, and is marketed in Japan by Xinglin Pharmaceutical and Kissei under the trade name beova for the treatment of overactive bladder.
On December 23, 2020, it was approved for marketing by the United States FDA under the trade name gemtesa.
